PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews
BioStock: PHI grows its network of collaborations
BioStock caught up with PHI’s CEO Patrik Eschricht to ask about his outlook for the growing number of academic collaborations and sales partnerships.
PostNews: Press Release
PHI bolsters Nordic sales presence with new distribution agreement between Altium and Kem-En-Tec Nordic
PHI is pleased to announce a new distribution agreement between its global distribution partner, Altium, and Kem-En-Tec Nordic, a lab supplier dedicated to supporting BioScience labs in Denmark, Sweden, Norway, Finland and Iceland.
PostNews: Press Release
PHI expands to Spanish and Portuguese markets through Altium’s new subcontract with Paralab
PHI is pleased to announce a strategic expansion into the Spanish and Portuguese markets, facilitated by a new subcontract between its global distribution partner, Altium, and Paralab.
PostNews: Press Release
PHI partners with University College London to use HoloMonitor in a first clinical research project
PHI is excited to announce a strategic partnership with University College London (UCL). Under this collaboration, PHI will lend a HoloMonitor® M4FL system for use in an ongoing research project at UCL, which runs alongside a clinical trial. This partnership represents PHI’s first direct step in a hospital setting to explore the clinical applications of its innovative technology.
PostNews: Press Release
PHI terminates agreement regarding liquidity provider
PHI today announces that the Company has terminated the liquidity provider agreement with Pareto Securities AB. The agreement will expire on July 31, 2024.
PostNews
BioStock: PHI “It’s the right moment to capitalize on regenerative medicine momentum.”
BioStock contacted CEO Patrik Eschricht for an update on the company’s progress and how PHI will capitalize on the current momentum.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
BioStock: Shift to regenerative medicine increases growth prospects for PHI
BioStock talked to our CEO, Patrik Eschricht, for an operational overview and to learn about the current behind-the-scenes developments, as PHI has a growth trajectory that is on a notable upward trend, marked by its highest-ever sales performances in the last quarter.
BioStock: PHI “We aim to revolutionize the regenerative medicine market“
BioStock talked to PHI’s CEO, Patrik Eschricht, about the eventful past year and his vision for the company’s future within regenerative medicine.
BioStock: PHI’s CEO reflects on the Company’s momentum
BioStock reached out to PHI’s CEO, Patrik Eschricht, to delve into what latest developments have contributed to the heightened enthusiasm surrounding the company.
BioStock: Altium fuels PHI’s forward drive
BioStock connects with Goran Dubravčić, Altium’s CEO and PHI’s newly appointed Chairman of the Board, to explore the current pivotal developments and their impact on PHI’s trajectory.
